ReviewGut2015
Does the microbiota play a role in the pathogenesis of autoimmune diseases?
Review in Gut, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04322500 (Intestinal Microbiota), which is not on this map. Cited by 103 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intestinal Microbiota: a New Target for Chalaziosis Treatment in Children
Who cites it
103 citing papers in PubMed, 1 synthesis or guideline pooled it, 214 citations in OpenAlex.
- The role of gut microbiota in autoimmune disease progression and therapy: a comprehensive synthesis.Frontiers in microbiomes · 2025Pooled it
- Intestinal microbiome: a new target for chalaziosis treatment in children?European journal of pediatrics · 2021Trial
- Whey Proteins and Immunity: Mechanisms Underlying Immune System Reinforcement and Protection Against Viral and Bacterial Infections.Nutrients · 2026Review
- A human fecal metaproteomic dataset from celiac disease patients on gluten-free diet with or without poly-autoimmunity.Data in brief · 2026Article
- Distinct gut microbiota profiles in acute vs. chronic sinusitis: potential biomarkers.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Article
- Article
- Evaluating the Efficacy of Secondary Metabolites in Antibiotic-Induced Dysbiosis: A Narrative Review of Preclinical Studies.Antibiotics (Basel, Switzerland) · 2025Review
- From Dysbiosis to Disease: The Microbiome's Influence on Uveitis Pathogenesis.Microorganisms · 2025Review
- Efficacy of sclareol based on 16S rDNA sequencing in modulating gut microbiota composition in estradiol-treated mice.Bioscience of microbiota, food and health · 2025Article
- Potential Pathogens Associated with Colorectal Cancer.Current pharmaceutical biotechnology · 2025Review
- Exploring the relationship betweenComputational and structural biotechnology journal · 2024Review
- Prevalence of delivery mode in an Italian nationwide cohort with celiac disease: a SIGENP multicenter retrospective study (the CD-deliver-IT).Italian journal of pediatrics · 2024Article
- Gut microbiota and chronic rhinosinusitis: a two-sample Mendelian randomization study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024Article
- Review
- Aggregatibacter Actinomycetemcomitans With Periodontitis and Rheumatoid Arthritis.International dental journal · 2024Article
- Lipid metabolism disorder in diabetic kidney disease.Frontiers in endocrinology · 2024Review
- Hungatella hathewayi impairs the sensitivity of colorectal cancer cells to 5-FU through decreasing CDX2 expression.Human cell · 2023Article
- Gut mycobiome as a potential non-invasive tool in early detection of lung adenocarcinoma: a cross-sectional study.BMC medicine · 2023Article
- Review
- Causal effects of gut microbiome on autoimmune liver disease: a two-sample Mendelian randomization study.BMC medical genomics · 2023Article
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The microbiota of the human metaorganism is not a mere bystander. These microbes have coevolved with us and are pivotal to normal development and homoeostasis. Dysbiosis of the GI microbiota is associated with many disease susceptibilities, including obesity, malignancy, liver disease and GI pathology such as IBD. It is clear that there is direct and indirect crosstalk between this microbial community and host immune response. However, the precise mechanism of this microbial influence in disease pathogenesis remains elusive and is now a major research focus. There is emerging literature on the role of the microbiota in the pathogenesis of autoimmune disease, with clear and increasing evidence that changes in the microbiota are associated with some of these diseases. Examples include type 1 diabetes, coeliac disease and rheumatoid arthritis, and these contribute significantly to global morbidity and mortality. Understanding the role of the microbiota in autoimmune diseases may offer novel insight into factors that initiate and drive disease progression, stratify patient risk for complications and ultimately deliver new therapeutic strategies. This review summarises the current status on the role of the microbiota in autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.